Lillys Easy-to Use Once-Weekly GLP-1 Agonist Trulicity Approved in Europe Twitter Summary: Lillys Trulicity, a once-weekly GLP-1 agonist available in US, has now been approved in Europe On November 25, Eli Lillys Trulicity (dulaglutide) was approved in Europe for type 2 diabetes
First, most human data comes from small cosmetic studies focused on efficacy endpoints such as wrinkle depth or skin firmness, not from trials designed and powered to detect rare adverse events
Because tirzepatide is a dual GIP/GLP-1 receptor agonist, its pharmacokinetic profile differs slightly from pure GLP-1 agonists
But certain scenarios warrant professional guidance
Common side effects : The most common side effects include temporary increased pain at the injection site, swelling, and stiffness in the heel
For example, 31% of respondents interested in medications are also interested in programs such as WeightWatchers